Denali Therapeutics (NASDAQ:DNLI) managed to raise $250 million at a post-money valuation of $1.58 billion. This has put Denali Therapeutics on the list for one of the largest biotechnology IPOs of 2017.
If Denali is able to exercise the full shoe, it would manage to bring in a total of $287 million, if not more.
Currently, the company’s stock is trading at $22.
At the moment, Denali is working with patients with Alzheimer’s disease, Lou Gehrig’s disease, Parkinson’s disease, and ALS. The company is headed by a team of specialists dedicated to finding treatments for these diseases, including Ryan J. Watts, Alexander O. Schuth, Marc Tessier-Lavigne, Carole Ho, and Steve E. Krognes. Watts brings with him a wealth of knowledge about blood-brain barrier therapies; Schuth has experience leading clinical stage development programs; Tessier-Lavigne is one of the top neuroscientists in the world; Ho has years worth of clinical development experience; and Krognes provides the company with operational and corporate finance experience.
Featured Image: twitter
